With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?
It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...
STAT16h
Pharmalittle: We’re reading about an FDA hold on an Amgen obesity drug, imported Canadian drugs, and more
The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...
Lilly needs a plan to spur weight-loss drug sales, investors say
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
Will This New GLP-1 Drug be More Powerful Than Ozempic?
CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.
Medicine Buffalo10h
Ophthalmic complications in patients on antidiabetic GLP-1 medications are concerning neuro-ophthalmologists
A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...
Prescriptions for weight loss drugs are skyrocketing, especially among young women. Experts think they know why.
The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...
Daily4h
Injection Tirzepatide may help treat Congenital Generalized Lipodystrophy: Case Report:
Congenital generalized lipodystrophy (CGL) is a rare autosomal recessive disorder characterized by a near-total absence of ...
Zacks.com on MSN2d
Eli Lilly Stock Before Q4 Earnings: To Buy or Not to Buy?
Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks ...
Yahoo Finance3d
With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?
We could point out that tirzepatide, the active ingredient in Mounjaro and Zepbound, is still undergoing many clinical trials and should earn key label expansions. Last year, the medicine aced a ...